Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention

Abstract

Background Radiologists have been administering gadolinium-based contrast agents (GBCA) in magnetic resonance imaging for several decades, so that there is abundant experience with these agents regarding allergic-like reactions, nephrogenic systemic fibrosis (NSF) and gadolinium retention in the brain. Methods This review is based on a selective literature search and reflects the current state of research on acute adverse effects of GBCA, NSF and brain retention of gadolinium. Results Due to the frequent use of GBCA, data on adverse effects of these compounds are available in large collectives. Allergic-like reactions occurred rarely, whereas severe acute reactions were very rarely observed. Systemic changes in NSF also occur very rarely, although measures to avoid NSF resulted in a significantly reduced incidence of NSF. Due to gadolinium retention in the body after administration of linear MR contrast agents, only macrocyclic preparations are currently used with few exceptions. Clear clinical correlates of gadolinium retention in the brain could not be identified so far. Although the clinical added value of GBCA is undisputed, individual risks associated with the injection of GBCA should be identified and the use of non-contrast enhanced MR techniques should be considered. Alternative contrast agents such as iron oxide nanoparticles are not clinically approved, but are currently undergoing clinical trials. Conclusion GBCA have a very good risk profile with a low rate of adverse effects or systemic manifestations such as NSF. Gadolinium retention in the brain can be minimized by the use of macrocyclic GBCA, although clear clinical correlates due to gadolinium retention in the brain following administration of linear GBCA could not be identified yet. Key Points: Citation Format

Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review

“…Another point in favour of MRI is the elimination of potential allergic reactions to iodine-containing contrast media. Gadolinium-based contrast agents show a very low risk of adverse events such as nephrogenic systemic fibrosis [40] . By contrast, we want to emphasise that 18 F-FDG PET-CT should only be used in highly selected cases, such as men with pure seminomatous postchemotherapy residual disease.…”

Facile Synthesis of Rigid Binuclear Manganese Complexes for Magnetic Resonance Angiography and SLC39A14-Mediated Hepatic Imaging

“…Among them, gadolinium­(III)-based CAs are predominantly used in clinics due to their slow electron spin relaxation and effective magnetic moment . However, commercially available gadolinium­(III)-based CAs have been reported to cause gadolinium deposition in the brain and bones and the linear ones were associated with the nephrogenic systemic fibrosis. − The US Food and Drug Administration has issued warnings regarding their clinical application due to these adverse effects . Recently, there has been growing interest in developing gadolinium-free CAs with lower toxicity and better tolerance, among which manganese­(II)-based complexes have been investigated due to their comparable electron spin relaxation, many of which have been recently reviewed. − …”

Development of cationic peptide-based hydrogels loaded with iopamidol for CEST-MRI detection

“…In the last few years, the wide use of gadolinium( iii ) based paramagnetic complexes as MRI contrast agents (CAs) in clinical practice has been questioned due to the evidence that a certain number of free Gd ions may be retained and accumulated in body sites of patients receiving multiple doses of CAs. 1 Even for this reason, research in this field has been moving towards alternative solutions to image the human anatomy and to obtain functional information on the disease onset and development. In this context, new methods and techniques are emerging.…”